$AIMT News
Last published 5y ago
- 5y agoAIMTAimmune Presents New Clinical Data From Pooled Safety Analysis in Patients Treated With PALFORZIA® for up to ~3.5 YearsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE1, RAMSES, ARTEMIS2) and three open-label extension (ARC0043, ARC008, ARC011) trials of PALFORZIA® [Peanut (Arachis hypogaea) ...
- 5y agoAIMTEuropean Commission Approves Aimmune’s PALFORZIA® as First-Ever Treatment for Peanut Allergy in the EUBusiness WireVEVEY, Switzerland & LONDON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc., a Nestlé Health Science Company, today announced that the European Commission (EC) has approved PALFORZIA® [defatted powder of Arachis hypogaea L., semen (peanuts)] for the treatment of peanut allergy. PALFORZIA is indicated in patients aged 4 to 17 years with a confirmed diagnosis of peanut allergy in conjunction with a pea ...
- 6y agoAIMTNestlé completes acquisition of Aimmune TherapeuticsGlobeNewswireVevey, October 14, 2020 Nestlé completes acquisition of Aimmune Therapeutics Nestlé announced today the successful completion of its acquisition of Aimmune Therapeutics, Inc. (Nasdaq: AIMT)....
- 6y agoAIMTNestlé announces results of tender offer for Aimmune Therapeutics, Inc.GlobeNewswireVevey, October 13, 2020 Nestlé announces results of tender offer for Aimmune Therapeutics, Inc. Société des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its...
- 6y agoAIMTNestlé announces results of tender offer for Aimmune Therapeutics, Inc.PR NewswireSociété des Produits Nestlé S.A. ("Nestlé") today announced the results of the tender offer by its wholly-owned subsidiary, SPN MergerSub, Inc....
- 6y agoKBLMADAPAIMTIMVT+3Life-Saving Advancements, Treatments Delivered by Companies Invested in InnovationPR NewswireInnovation and breakthroughs in the biotech industry are essential to identifying and providing life-saving treatments. Companies that invest...
- 6y agoAIMTMTEMINZYPSTX+4Longitude Capital Raises $585 Million Fund to Invest in Transformative Healthcare CompaniesGlobeNewswire- Longitude Venture Partners IV will build on the Firm’s commitment to improve clinical outcomes, enhance patient quality of life, and drive efficiency in healthcare delivery - - In 2020 to date,...
- 6y agoAIMTNestlé commences tender offer for Aimmune Therapeutics, Inc.PR NewswireSociété des Produits Nestlé S.A. ("Nestlé") announced that its wholly-owned subsidiary, SPN Merger Sub, Inc. ("Purchaser"), is commencing today a...
- 6y agoMNTAONDKAIMTOTELMoore Kuehn Encourages MNTA, AIMT, ONDK, and OTEL Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 03, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning...
- 6y agoHONAMGNCRMPFE+16Stocks making the biggest moves in the premarket: Honeywell, Amgen, Salesforce, Apple, GE & moreCNBCThe stocks making the biggest moves in premarket trading include Honeywell, Amgen, Salesforce, Apple, GE, and more.
- 6y agoAIMTAimmune Therapeutics Enters Definitive Agreement with Sociétés des Produits Nestlé S.A., Part of Nestlé Health ScienceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it has entered into a definitive agreement for Sociétés des Produits Nestlé, S.A. to acquire Aimmune for $34.50 per share in an all-cash transaction, implying a fully-diluted equity v ...
- 6y agoAIMTLargest European Qualitative Study on Peanut Allergy Highlights Negative Impact of Avoidance and Fear of Accidental Peanut Allergy Reactions on Allergic Individuals and Their CaregiversBusiness WireLONDON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that findings from APPEAL-2 (Allergy to Peanuts ImPacting Emotions And Life-2), the largest cross-sectional, pan-European, qualitative study to evaluate the psychosocial burden of living with peanu ...
- 6y agoAIMTAimmune Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Virtual ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 10:55 a.m. E.T ...
- 6y agoAIMTAimmune Therapeutics Announces Second Quarter 2020 Financial Results and Provides Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and six months ended June 30, 2020.
- 6y agoAIMTAimmune Therapeutics to Host Conference Call and Webcast to Discuss Second Quarter 2020 Financial Results and Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, July 30, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and six months ended June 30, 2020, and recent operational ...
- 6y agoAIMTFull Results of Aimmune’s Pivotal Phase 3 European ARTEMIS Trial of PALFORZIA® Published in The Lancet Child & Adolescent HealthBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that complete results from its pivotal phase 3 European ARTEMIS trial (AR101 Trial in Europe Measuring Oral Immunotherapy Success) of PALFORZIA® [Peanut (Arachis hypogaea) Allergen Powder ...
- 6y agoAIMTAimmune Appoints Narinder Singh as Executive Vice President of Technical OperationsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced the appointment of Narinder Singh as Executive Vice President, Technical Operations. Mr. Singh is a proven biopharmaceutical executive with over two decades of deep technical, operational ...
- 6y agoAIMTAimmune Therapeutics to Present at the Goldman Sachs 41st Annual Global Healthcare ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in a fireside chat at the Goldman Sachs 41st Annual Global Healthcare Conference on Tuesday, June 9, 2020 at 11:20 a.m. E.T.
- 6y agoAIMTNew PALFORZIA™ Data on Long-Term Safety, Efficacy and Immunomodulation and New Data on Patient Satisfaction with PALFORZIA Treatment to be Presented at EAACI 2020 CongressBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced it will present important new long-term safety, efficacy and immunological data from ARC004, an open-label, rollover study of the landmark pivotal PALISADE trial of PALFORZIA™ [Peanut (Arachis hypoga ...
- 6y agoAIMTLargest European Quantitative Study on Peanut Allergy Confirms Significant Need, Burden and Psychosocial Impact of Peanut Allergy on Allergic Individuals and their CaregiversBusiness WireLONDON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for life-threatening food allergies, today announced that findings from APPEAL-1 (Allergy to Peanuts ImPacting Emotions And Life-1), a multi-dimensional pan-European study assessing the psychosocial effect and impact of living with peanut allergy, were published ...
- 6y agoAIMTAimmune Therapeutics Announces First Quarter 2020 Financial Results and Provides Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the quarter ended March 31, 2020.
- 6y agoAIMTAimmune Therapeutics to Host Conference Call and Webcast to Discuss First Quarter 2020 Financial Results and Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Monday, May 11, 2020, at 4:30 p.m. ET to discuss its financial results for the first quarter ended March 31, 2020, and recent operational highlights ...
- 6y agoAIMTAimmune Therapeutics to Present at the 19th Annual Needham Virtual Healthcare ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that its Chief Financial Officer, Eric Bjerkholt, will present at the 19th Annual Needham Virtual Healthcare Conference on Wednesday, April 15, 2020 at 2:50 p.m. E.T.
- 6y agoAIMTAimmune Announces First U.S. Patients Are Being Treated with Newly-Approved PALFORZIA™, the First Treatment for Peanut AllergyBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the first patients in the United States are being treated with PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first approved treatment for peanut allergy. Following ...
- 6y agoAIMTAimmune Announces New PALFORZIA™ Data Suggesting Increased Desensitization, Improved Tolerability and Continued Immunomodulation After 18 and 24 Months of TreatmentBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and bringing new treatments to people with potentially life-threatening food allergies, today announced new data from the clinical development program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first peanut allergy treatment approved by the U.S. Food and Dr ...
- 6y agoUBERYPFD3-ARETP'CNLOK+1Cramer's lightning round: I like Uber as a long-term playCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 6y agoBAXPSNPFPTAIMT+2Cramer's lightning round: I'm never going to go against Warren BuffettCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 6y agoAIMTAimmune Therapeutics Announces Fourth Quarter and Full Year 2019 Financial Results and Provides Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced financial results for the fourth quarter and full year 2019.
- 6y agoAIMTAimmune Therapeutics to Present at Upcoming Investor ConferencesBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will present at two upcoming investor conferences in March:
- 6y agoAIMTAimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2019 Financial Results and Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Thursday, February 27, 2020, at 4:30 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2019, and recent oper ...
- 6y agoAIMTAimmune Therapeutics Announces Additional $200 Million Equity Investment by Nestlé Health ScienceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that Nestlé Health Science will make an additional equity investment in Aimmune of $200 million, bringing Nestlé’s total investment in Aimmune to date to $473 million.
- 6y agoAIMTAimmune Licenses Exclusive Worldwide Rights to Xencor’s XmAb®7195 for the Development of Next-Generation Food Allergy TreatmentsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced it has obtained an exclusive worldwide license to develop and commercialize the investigational humanized monoclonal antibody XmAb®7195 from Xencor, Inc.
- 6y agoAIMTFLWSCVMCVS+4Cramer's lightning round: Investors are worried about CVS's Aetna acquisitionCNBC"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed.
- 6y agoAIMTFDA Approves First Drug for Peanut AllergyBloombergU.S. health regulators approved the first drug for children and teenagers with peanut allergies, marking a potential paradigm shift in treatment.
- 6y agoAIMTFDA Approves Aimmune’s PALFORZIA™ as First Treatment for Peanut AllergyBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced that the U.S. Food and Drug Administration (FDA) approved PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp]. PALFORZIA is the first approved treatment for patients with peanut a ...
- 6y agoESPRBMYAIMTKPTI+4Biotech Looks for Fireworks in First Quarter to Regain MomentumBloombergStudy results and regulatory actions in the first quarter may help reignite enthusiasm for biotech stocks. Here’s a look at some of the key catalysts investors are watching.
- 6y agoAIMTAimmune Therapeutics to Present at the 38th Annual J.P. Morgan Healthcare ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the 38th Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2020 at 2:30 p.m. P.T. in San Francisco.
- 6y agoAIMTAimmune to Participate in Three Upcoming Investor ConferencesBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Aimmune executive management team will participate in three upcoming investor conferences in November and December:
- 7y agoAIMTQuality of Life Outcomes from Two New Surveys Highlight Emotional Impact of Peanut Allergy and Need for New TreatmentsBusiness WireHOUSTON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented results from two new surveys that examined the effects of peanut allergy on health-related quality of life (HRQoL) among adults and caregivers in the United States. The findings reinforce the need for new treatments i ...
- 7y agoAIMTNew Data Presented at ACAAI 2019 Show Importance of Clinical History in Identifying AR101-Eligibile Patients for PALISADE Study without a Food ChallengeBusiness WireHOUSTON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today presented new data showing that a strong clinical history, in combination with evidence of peanut sensitization, is the optimal approach to identify peanut-allergic patients who are highly sensitive to peanut protein. These dat ...
- 7y agoAIMTAR101 Demonstrates Consistent Efficacy and Safety in New Analysis at ACAAI Comparing PALISADE and ARTEMIS Phase 3 Clinical DataBusiness WireHOUSTON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the results from a new analysis showing consistent efficacy and safety with AR101 across the phase 3 PALISADE and ARTEMIS trials, despite differing regions of study, entry criteria, therapeutic dosing periods and prim ...
- 7y agoAIMTNew Real-World Data Unveiled at ACAAI Indicates Comparable Clinical Practice Logistics to Implement Oral Immunotherapy and Environmental Allergy ShotsBusiness WireHOUSTON--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today revealed that the logistical needs for implementing oral immunotherapy (OIT) for food allergies, such as peanut allergy, into clinical practice is comparable to those for subcutaneous immunotherapy (SCIT) for environmental alle ...
- 7y agoAIMTAimmune Therapeutics Announces Third Quarter 2019 Financial Results and Provides Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced financial results for the quarter and nine months ended September 30, 2019 and provided operational highlights.
- 7y agoAIMTAimmune to Participate in the Credit Suisse 28th Annual Healthcare ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in a fireside chat at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 1:15 p.m. MST in Scottsdale, A ...
- 7y agoAIMTAimmune Therapeutics to Host Conference Call and Webcast to Discuss Third Quarter 2019 Financial Results and Recent Operational HighlightsBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that it will host a conference call on Wednesday, November 6, 2019, at 4:30 p.m. ET to discuss its financial results for the quarter ended September 30, 2019, and recent operational highlights.
- 7y agoAIMTAimmune to Present at the Cantor Global Healthcare ConferenceBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that its President and Chief Executive Officer, Jayson Dallas, M.D., will present at the Cantor Global Healthcare Conference on Thursday, October 3, 2019 at 8:20 a.m. E.T. in New York City.
- 7y agoAIMTFDA Allergenic Products Advisory Committee Votes to Support the Use of Aimmune’s PALFORZIA™ (AR101) for Peanut AllergyBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced that the Allergenic Products Advisory Committee (APAC) convened by the U.S. Food and Drug Administration (FDA) voted to support the use of AR101 (proposed trade name PALFORZIA™) in children and teens with pea ...
- 7y agoAIMTAimmune Stock Trading Halted Today; FDA Allergenic Products Advisory Committee (APAC) Meeting to Discuss PALFORZIA™ (AR101) for Peanut AllergyBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that NASDAQ has halted trading of the company’s common stock. The U.S. Food and Drug Administration (FDA) Allergenic Products Advisory Committee (APAC) is holding a meeting today from 8:30 a.m. to 4:30 p.m. ET to discuss ...
- 7y agoAIMTAimmune to Participate in Three Investor Conferences in SeptemberBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that members of the Aimmune executive management team will participate in three upcoming investor conferences in September:
- 7y agoAIMTAimmune Enrolls First Patient in Phase 2 Trial of AR201 for Egg AllergyBusiness WireBRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it has randomized its first patient in a phase 2 clinical trial of AR201 for the treatment of egg allergy. AR201, an investigational biological drug for use in oral immunotherapy for egg allergy, is the second deve ...